Cardamonin (oral gavage; 20, 40 or 80 mg/kg; once) treatments alleviates doxorubicin-induced cardiotoxicity and inhibits apoptosis in doxorubicin-challenged mice[4].
| Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] |
| Dosage: | 20, 40 or 80 mg/kg |
| Administration: | Oral gavage; 20, 40 or 80 mg/kg; once |
| Result: | Rescued the reduction of LVEF% and LVFS% by doxorubicin, reduced the increasement of serum LDH, CK-MB and Tn-T levels by doxorubicin in a dose-dependent manner, improved doxorubicin-induced histological changes, and attenuated collagen accumulation in cardiac sections by doxorubicin in a dose-dependent manner. |
| Animal Model: | Male C57BL/6 J mice (8 weeks old, 20-22 g)[4] |
| Dosage: | 20, 40 or 80 mg/kg |
| Administration: | Oral gavage; 20, 40 or 80 mg/kg; once |
| Result: | Rescued Bcl-2, and inhibited Bax and Caspase-3 cleavage in heart tissues from doxorubicin-challenged mice. |
